A highly absorbable branched-chain amino acid complex formulation and its process for promoting skeletal muscle repair
By forming a non-covalent encapsulation structure between chitosan oligosaccharide and branched-chain amino acids, the problem of hydrophobic aggregation and low adsorption and binding rate of branched-chain amino acid preparations in the gastrointestinal tract is solved, thereby improving the absorption and utilization efficiency of skeletal muscle repair.
Patent Information
- Application Number
- CN202611510965.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-28
- Publication Date
- 2026-11-17
AI Technical Summary
Existing branched-chain amino acid preparations exhibit hydrophobic aggregation in the gastrointestinal tract and have low intestinal mucosal adsorption and binding rates, resulting in low absorption and utilization efficiency by skeletal muscle.
The non-covalent interaction between chitosan oligosaccharide and branched-chain amino acids forms a physical encapsulation structure. By utilizing the non-covalent interactions such as electrostatic attraction and hydrogen bonding between the buffered microemulsion dispersion base liquid and chitosan oligosaccharide, the residence time of the formulation in the intestine is prolonged, thereby improving the adsorption and binding rate of the intestinal mucosa.
It improves the uniform dispersion of branched-chain amino acids in gastrointestinal fluid, prolongs their residence time in the intestine, increases intestinal adsorption and binding rate and body absorption efficiency, and enhances the material support for skeletal muscle repair.
Smart Images

Figure CN123101488A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of amino acid preparation technology, and in particular to a highly absorbable branched-chain amino acid complex preparation and process for promoting skeletal muscle repair. Background Technology
[0002] Branched-chain amino acids, mainly including leucine, isoleucine, and valine, play a direct role in promoting skeletal muscle protein synthesis, reducing muscle protein breakdown, and accelerating the repair of muscle micro-damage. They are currently widely used in sports nutrition supplements and rehabilitation preparations.
[0003] However, conventional free branched-chain amino acid preparations have certain absorption and utilization obstacles in practical applications. Because the molecular structure of branched-chain amino acids contains hydrophobic isopropyl and isobutyl side chains, they will spontaneously generate hydrophobic interactions and aggregate into clusters in an aqueous environment. The microscopic aggregation makes it difficult for the preparation to be evenly dispersed after entering the gastrointestinal digestive fluid, resulting in low solubility, clumping or precipitation, which limits the release of active ingredients.
[0004] Based on this, free branched-chain amino acids lack an effective affinity and retention mechanism with the intestinal mucosa, resulting in a short transit time in the intestine and a low adsorption and binding rate of the active ingredient by the intestinal mucosa. The physical dispersion problem and the intestinal absorption problem are superimposed, resulting in a large loss of branched-chain amino acids in conventional preparations before entering the blood circulation. The actual effective concentration absorbed into the body is low, which is difficult to meet the needs of rapidly promoting skeletal muscle repair. At present, common modification methods mostly focus on adding solubilizers to improve dispersibility, and rarely take into account the comprehensive design from the perspective of microscopic molecular structure encapsulation intervention and improving intestinal adhesion, which makes it difficult to fundamentally improve the overall absorption and utilization efficiency of the body. Summary of the Invention
[0005] The purpose of this invention is to provide a highly absorbable branched-chain amino acid complex formulation and process for promoting skeletal muscle repair, which solves the problem that existing branched-chain amino acid formulations cause hydrophobic aggregation in the gastrointestinal tract and have low adsorption and binding rates to the intestinal mucosa, resulting in low absorption and utilization efficiency of skeletal muscle.
[0006] To achieve the above objectives, the present invention provides the following technical solution:
[0007] In a first aspect, the present invention provides a highly absorbable branched-chain amino acid complex formulation for promoting skeletal muscle repair, employing the following technical solution:
[0008] The composite formulation forms a physical encapsulation structure through non-covalent interactions between chitosan oligosaccharides and branched-chain amino acids, which promotes skeletal muscle repair and enhances the adsorption and binding rate of the intestinal mucosa; the composite formulation comprises the following components in parts by weight:
[0009] Buffered microemulsion dispersion base: 735 to 1500 parts;
[0010] L-Leucine: 30 to 50 parts;
[0011] L-Isoleucine: 15 to 25 parts;
[0012] L-valine: 15 to 25 parts;
[0013] Taurine: 3 to 8 parts;
[0014] Grape seed extract: 0.5 to 2 parts;
[0015] Chitosan oligosaccharide: 10 to 20 parts.
[0016] By employing the above technical solution, the buffered microemulsion dispersion base acts as a basic dispersion medium, facilitating the initial dispersion of L-leucine, L-isoleucine, and L-valine. Taurine and grape seed extract are introduced into the formulation to assist in regulating cell permeability and anti-oxidation. Relying on the non-covalent interaction between chitosan oligosaccharide and branched-chain amino acid molecules, a physical encapsulation structure can be formed within the system, which can, to a certain extent, hinder the spontaneous aggregation of branched-chain amino acids in the aqueous environment. After entering the intestinal environment, the active groups on the chitosan oligosaccharide molecular chain bind to the mucoprotein on the intestinal mucosa, which helps to prolong the residence time of the formulation in the intestine, thereby improving the adsorption and binding of branched-chain amino acids on the intestinal mucosa, increasing the concentration entering the bloodstream, and providing a material basis for skeletal muscle protein synthesis and repair.
[0017] Preferably, the buffered microemulsion dispersion is composed of deionized water, a buffer system consisting of citric acid and sodium citrate dihydrate, and soybean lecithin, and the pH value of the buffered microemulsion dispersion is constantly controlled within the range of 3.5 to 4.5.
[0018] By adopting the above technical solution, the buffer system composed of citric acid and sodium citrate dihydrate can maintain the pH value of the solution in the range of 3.5 to 4.5. Under slightly acidic conditions, soybean lecithin molecules tend to self-assemble to form microemulsion droplets and act as dispersion carriers. In addition, this pH environment is also conducive to maintaining the protonated state of chitosan oligosaccharide molecules, creating conditions for subsequent non-covalent binding with branched amino acids.
[0019] Preferably, the degree of polymerization of the chitosan oligosaccharide is between 2 and 10, the number average molecular weight is between 500 Da and 2000 Da, and the degree of deacetylation is ≥90%; the proanthocyanidin mass fraction in the grape seed extract is ≥95%.
[0020] By adopting the above technical solution, chitosan oligosaccharides with a degree of polymerization of 2 to 10 and a number-average molecular weight of 500 Da to 2000 Da are selected. The good water solubility and molecular flexibility are mainly used to unfold the molecular chain to coat the branched amino acids. The degree of deacetylation ≥90% allows more free amino groups to be retained on the chain segments, thereby providing binding sites for interaction with branched amino acids and intestinal mucosa. Grape seed extract with a proanthocyanidin mass fraction ≥95% focuses on exerting antioxidant properties to help clear free radicals generated in the micro-damage area of muscle.
[0021] Secondly, the present invention provides a process for a highly absorbable branched-chain amino acid complex formulation that promotes skeletal muscle repair, comprising the following steps:
[0022] L-Leucine, L-Isoleucine and L-Valine were added to a buffer microemulsion dispersion solution controlled at a constant temperature. After stirring and mixing, taurine and grape seed extract were added in sequence, and stirring was continued to obtain a homogeneous stock solution.
[0023] The homogenized stock solution was pumped into an ultrasonic reactor with a refrigerant jacket for ultrasonic treatment, which opened the hydrophobic cluster structure of the branched amino acid molecules and exposed the active sites of the side chains.
[0024] After the ultrasound is completed, the liquid is transferred to a constant temperature reactor and chitosan oligosaccharide is slowly added. The reaction is continued while maintaining a constant pH value in the reaction system to promote the formation of a weak bond cross-linking coating structure between chitosan oligosaccharide and branched-chain amino acid molecules. After the reaction is completed, the temperature is rapidly reduced to terminate the reaction.
[0025] After the reaction is terminated, the liquid is sent to a falling film concentrator for vacuum negative pressure concentration. Then, the concentrate is pumped into a centrifugal spray drying tower for low-temperature spray drying. The bottom powder is collected and sieved to obtain the target compound formulation.
[0026] By adopting the above technical solution, in terms of the entire preparation process and related mechanisms, since the isopropyl and isobutyl side chains of branched amino acid molecules are hydrophobic, they will aggregate into clusters in water. After adding the buffer microemulsion dispersion base liquid, the interfacial tension of the microemulsion droplets can be used to aggregate the aggregates to obtain preliminary dispersion.
[0027] Next, after ultrasonic treatment, the acoustic cavitation effect generated in the system, along with the accompanying microjets and shear forces, are applied to the amino acid aggregates. This process helps to weaken the hydrophobic interactions between molecules, promotes the release of more free branched amino acid molecules, and increases the exposure probability of side chain active sites, leaving room for subsequent coating reactions.
[0028] During the subsequent isothermal reaction stage, under the constraints of a pH environment of 3.5 to 4.5, some of the free amino groups on the chitosan oligosaccharide molecular chain tend to protonate and form positively charged groups, while some of the carboxyl groups of the branched amino acids also dissociate into negatively charged groups, resulting in electrostatic attraction between the two. At the same time, intermolecular hydrogen bonds can be formed between the hydroxyl and amino groups of chitosan oligosaccharide and the amino and carboxyl groups of amino acids. Relying on the combined effects of electrostatic attraction and non-covalent bonds such as hydrogen bonds, the long chain of chitosan oligosaccharide will wrap around the branched amino acid molecules. After the reaction is completed, the temperature is rapidly reduced, which significantly slows down the molecular thermal motion in the system, helping to maintain and solidify the weak bond cross-linking state.
[0029] The vacuum negative pressure concentration in the post-processing stage can remove moisture at a relatively low temperature, avoiding the risk of non-covalent bond breakage caused by high temperature. Combined with low temperature spray drying, as the droplet surface loses water and forms a crust, the original physical encapsulation structure is preserved in the final formulation powder.
[0030] Preferably, the steps of adding L-leucine, L-isoleucine, and L-valine to a buffer microemulsion dispersion under constant temperature conditions, stirring and mixing, then sequentially adding taurine and grape seed extract, and continuing stirring to obtain a homogeneous stock solution include: controlling the constant temperature conditions of the buffer microemulsion dispersion at 15 to 25°C, adding L-leucine, L-isoleucine, and L-valine, and stirring at 150 to 300 rpm for 20 to 30 minutes; then sequentially adding taurine and grape seed extract, and continuing stirring for 10 to 20 minutes.
[0031] By adopting the above technical solution, the constant temperature condition of 15 to 25°C helps to maintain the relative stability of the microemulsion structure of the base liquid, reduce the demulsification of lecithin vesicles caused by high temperature, and, in conjunction with the set stirring speed and duration, promote the gradual wetting and dispersion of the added powder material in the microemulsion, reducing the probability of clumping due to excessive local concentration.
[0032] Preferably, before ultrasonic treatment, the homogenized stock solution is filtered through a multi-stage precision microporous membrane with a pore size of 5 to 10 μm to remove insoluble impurities introduced by the raw materials.
[0033] By adopting the above technical solution, insoluble particles with larger particle sizes are filtered out in advance, mainly to reduce interference with the transmission of sound energy during subsequent ultrasonic treatment. At the same time, it can prevent impurities from acting as crystal nuclei in the chitosan oligosaccharide coating stage to a certain extent, thereby reducing the generation of non-targeted agglomeration and precipitation.
[0034] Preferably, the temperature of the molten material is maintained below 30°C, the ultrasonic frequency is set to 20 to 40 kHz, and the ultrasonic power density is 0.5 to 1.5 W / cm³. 3 The ultrasonic treatment time is 15 to 30 minutes.
[0035] By adopting the above technical solution, the heating temperature is limited to below 30℃, which aims to alleviate the system temperature rise caused by the heat generated by the ultrasound process itself. The use of medium and low frequency ultrasound in the range of 20 to 40 kHz and the corresponding power density aims to output a moderate cavitation effect to assist the depolymerization of hydrophobic clusters, while avoiding excessive input energy that could damage the covalent bonds of amino acids.
[0036] Preferably, the temperature for the isothermal reaction of adding chitosan oligosaccharide is set to 20 to 35°C, the stirring speed is 50 to 100 rpm, and the reaction time is 45 to 90 min; ice water is introduced into the jacket of the reactor to rapidly cool the system to 10 to 15°C within 10 to 15 min to terminate the reaction.
[0037] By adopting the above technical solution, the reaction temperature is set in the range of 20 to 35°C, which is conducive to the gradual formation of non-covalent bonds. The relatively low stirring speed controls the fluid shear force, so that the initially formed weak bond coating structure is not destroyed. After the reaction, the temperature is quickly reduced to 10 to 15°C, which can slow down the molecular thermal motion in the system and help maintain the microstructure of the formulation.
[0038] Preferably, vacuum negative pressure concentration is carried out at a vacuum degree of -0.08MPa to -0.10MPa and an evaporation temperature controlled between 40 and 45°C, and the concentration of solids in the concentrated liquid is controlled to be between 25% and 35%.
[0039] By adopting the above technical solution, the set vacuum environment lowers the boiling point of water in the system so that evaporation and concentration can be carried out between 40 and 45°C, and the concentration of the concentrated solids falls between 25% and 35%, so that the liquid exhibits a viscosity suitable for subsequent pumping and atomization operations.
[0040] Preferably, the air inlet temperature is set to 110 to 130°C and the air outlet temperature is controlled to 45 to 60°C for low-temperature spray drying; the air is then sieved through a 60 to 80 mesh vibrating screen at an environment of 20 to 25°C.
[0041] By adopting the above technical solution, the moisture on the surface of the droplets is vaporized by the air intake, while the air outlet temperature is between 45 and 60°C. The purpose is to avoid thermal damage to the internal components of the particles as much as possible. The subsequent vibrating sieving operation is used to remove some fine powder and agglomerates in order to improve the powder flowability and particle size uniformity of the final product.
[0042] In summary, the present invention has at least one of the following beneficial technical effects:
[0043] 1. This invention utilizes a buffered microemulsion dispersion medium with pH controlled within a specific range as the dispersion medium. It relies on the electrostatic attraction and non-covalent interactions such as hydrogen bonding between chitosan oligosaccharide and branched-chain amino acids to form a physical encapsulation structure around the amino acid molecules. This technical feature inhibits the hydrophobic aggregation of branched-chain amino acid side chains in water, maintains good uniform dispersion in gastrointestinal fluids, and reduces the probability of clumping and precipitation after powder administration.
[0044] 2. This invention improves the adsorption and binding rate of the formulation in the intestine and the absorption efficiency of the body. The compound formulation uses chitosan oligosaccharide as the outer coating material. When it enters the intestine, the active groups on the chitosan oligosaccharide chain will bind with the mucin on the surface of the intestinal mucosa, appropriately prolonging the residence time of amino acids in the intestine, improving the situation where conventional free amino acids are not fully absorbed due to the rapid passage of the intestine, thereby increasing the concentration of amino acids entering the blood circulation and providing stable material support for the repair of skeletal muscle damage.
[0045] 3. In the preparation process of this invention, the amino acid clusters are first depolymerized by medium- and low-frequency ultrasonic treatment. Then, the encapsulation structure is promoted under relatively low constant temperature conditions, and rapid cooling is used to slow down the molecular thermal motion to solidify the microstructure. In the post-processing dehydration stage, vacuum negative pressure concentration and low-temperature spray drying are used to avoid the conventional high-temperature processing environment, reduce the damage of heat energy to non-covalent weak bonds and antioxidant components such as grape seed extract, and maintain the structural integrity of the final powder product. Attached Figure Description
[0046] Figure 1 A bar chart comparing the supramolecular composite assembly mechanism of this invention, wherein... Figure 1 (a) is a comparison of the absorbance of free aminoninhydrin in samples A, B, and C. Figure 1 (b) is a comparison diagram of the powder wetting contact angles of L-leucine monomer, dry-mixed powder of Comparative Example 1 and finished product of Example 2;
[0047] Figure 2 This is a comparison chart of the powder formulation dispersion stability of the present invention, wherein... Figure 2 (a) is a comparison chart of the mixing, wetting, and complete dispersion times for each test subject. Figure 2 (b) is a comparison chart of the static suspension sedimentation rates of the aqueous solutions of each test object;
[0048] Figure 3 This is a comparison chart of the in vitro mucin adsorption and binding rates of the present invention;
[0049] Figure 4 This is a comparison chart of the cumulative dissolution rate of simulated gastrointestinal fluid at different time points according to the present invention;
[0050] Figure 5 This is a comparison chart of the low-temperature activation and antioxidant potency retention throughout the entire process of the present invention, wherein, Figure 5 (a) is a comparison chart of proanthocyanidin retention rates for each test subject. Figure 5 (b) is a comparison chart of the browning indices of the various test subjects. Figure 5 (c) is a comparison chart of DPPH free radical scavenging rates for each test subject. Detailed Implementation
[0051] The following is in conjunction with the appendix Figure 1 -Appendix Figure 5 The present invention will be further described in detail below.
[0052] The main raw materials and reagents used in the following examples and comparative examples have the following sources and specifications. Reagents not specifically mentioned are all commercially available analytical grade or higher grade products.
[0053] L-Leucine, CAS No. 61-90-5, purity ≥99.0%;
[0054] L-Isoleucine, CAS No. 73-32-5, purity ≥99.0%;
[0055] L-valine, CAS number 72-18-4, purity ≥99.0%;
[0056] Chitosan oligosaccharide, CAS number 148411-57-8, has a degree of polymerization ranging from 2 to 10, a number-average molecular weight ranging from 500 Da to 2000 Da, and a degree of deacetylation ≥90%;
[0057] Taurine, CAS number 107-35-7, purity ≥99.0%;
[0058] Grape seed extract, with a proanthocyanidin content ≥95%, wherein the CAS number of the proanthocyanidins is 4852-22-6;
[0059] Soy lecithin, CAS number 8002-43-5, contains phosphatidylcholine at a mass fraction of ≥70%.
[0060] In this invention, the units of measurement for all materials and solvents are uniformly referred to as parts by weight.
[0061] Preparation Example 1:
[0062] This preparation example provides a method for preparing a specific buffered microemulsion dispersion, including the following steps:
[0063] Take 100 parts of deionized water, add citric acid and sodium citrate dihydrate to prepare a buffer solution with a concentration of 0.05 mol / L and a constant pH of 3.5. Take 1.0 part of soybean lecithin and dissolve it in 2.0 parts of anhydrous ethanol. Then slowly add it dropwise to the buffer solution. Turn on the high shear disperser and set the speed to 8000 rpm. Shear disperse for 10 min to form a uniform semi-transparent microemulsion.
[0064] The resulting specific buffered microemulsion dispersion is then used for later use. This specific buffered microemulsion dispersion is named Buffered Microemulsion Dispersion A.
[0065] Preparation Example 2:
[0066] This preparation example provides a method for preparing a specific buffered microemulsion dispersion, including the following steps:
[0067] Take 100 parts of deionized water, add citric acid and sodium citrate dihydrate to prepare a buffer solution with a concentration of 0.1 mol / L and a constant pH of 4.0. Take 2.0 parts of soybean lecithin and dissolve it in 4.0 parts of anhydrous ethanol. Then slowly add it dropwise to the buffer solution. Turn on the high shear disperser and set the speed to 9000 rpm. Shear disperse for 12 min to form a uniform semi-transparent microemulsion.
[0068] The resulting specific buffered microemulsion dispersion is then ready for use. This specific buffered microemulsion dispersion is named Buffered Microemulsion Dispersion B.
[0069] Preparation Example 3:
[0070] This preparation example provides a method for preparing a specific buffered microemulsion dispersion, including the following steps:
[0071] Take 100 parts of deionized water, add citric acid and sodium citrate dihydrate to prepare a buffer solution with a concentration of 0.15 mol / L and a constant pH of 4.5. Take 3.0 parts of soybean lecithin and dissolve it in 6.0 parts of anhydrous ethanol. Then slowly add it dropwise to the buffer solution. Turn on the high shear disperser and set the speed to 10,000 rpm. Shear disperse for 15 min to form a uniform semi-transparent microemulsion.
[0072] The resulting specific buffered microemulsion dispersion is then ready for use. This specific buffered microemulsion dispersion is named Buffered Microemulsion Dispersion C.
[0073] Example 1:
[0074] This embodiment provides a process for a highly absorbable branched-chain amino acid complex formulation that promotes skeletal muscle repair, comprising the following steps:
[0075] Take 735 parts of buffer microemulsion dispersion A, keep the temperature at 15℃, add 30 parts of L-leucine, 15 parts of L-isoleucine and 15 parts of L-valine, turn on the anchor stirrer and stir at 150 rpm for 20 min, then add 3 parts of taurine and 0.5 parts of grape seed extract in sequence, and continue stirring for 10 min.
[0076] The solution is filtered through a multi-stage precision microporous membrane with a pore size of 5μm to remove trace amounts of insoluble impurities introduced by raw materials such as grape seed extract. The filtered homogenized stock solution is then pumped into an ultrasonic reactor equipped with a refrigerant jacket, maintaining the solution temperature below 30℃. The ultrasonic generator is then activated at a frequency of 20kHz and a pressure of 0.5W / cm². 3 Sonication was performed at power density for 15 minutes.
[0077] After the ultrasound was completed, the liquid was transferred to a constant temperature reactor and the temperature was set to 20°C. Ten parts of chitosan oligosaccharide were slowly added while stirring at 50 rpm. The pH of the reaction system was kept constant and the reaction was continued for 45 minutes.
[0078] After the reaction is complete, ice water is introduced into the jacket to rapidly cool the system to 10°C within 10 minutes to terminate the reaction. The liquid is then sent to a falling film concentrator and concentrated to a solids concentration of 25% under a vacuum of -0.08 MPa and an evaporation temperature of 40°C.
[0079] The concentrate is pumped into a centrifugal spray drying tower, the inlet air temperature is set to 110℃ and the outlet air temperature is controlled to 45℃ for spray drying, the bottom powder is collected and sieved through a 60-mesh vibrating screen at 20℃ to obtain the target compound preparation.
[0080] Example 2:
[0081] This embodiment provides a process for a highly absorbable branched-chain amino acid complex formulation that promotes skeletal muscle repair, comprising the following steps:
[0082] Take 1000 parts of buffer microemulsion dispersion base liquid B, keep the temperature constant at 20℃, add 40 parts of L-leucine, 20 parts of L-isoleucine and 20 parts of L-valine, turn on the anchor stirrer, stir at 200 rpm for 25 min, then add 5 parts of taurine and 1 part of grape seed extract in sequence, and continue stirring for 15 min.
[0083] The solution is filtered through a multi-stage precision microporous membrane with a pore size of 8μm to remove trace amounts of insoluble impurities introduced by raw materials such as grape seed extract. The filtered homogenized stock solution is then pumped into an ultrasonic reactor equipped with a refrigerant jacket to maintain the temperature of the solution below 30℃. The ultrasonic generator is then turned on at a frequency of 30kHz and a speed of 1.0W / cm². 3 Sonication was performed at power density for 20 minutes.
[0084] After the ultrasound was completed, the liquid was transferred to a constant temperature reactor and the temperature was set to 25°C. 15 parts of chitosan oligosaccharide were slowly added while stirring at 80 rpm. The pH of the reaction system was kept constant and the reaction was continued for 60 min.
[0085] After the reaction is complete, ice water is introduced into the jacket to rapidly cool the system to 12°C within 12 minutes to terminate the reaction. The liquid is then sent to a falling film concentrator and concentrated to a solids concentration of 30% under a vacuum of -0.09 MPa and an evaporation temperature of 42°C.
[0086] The concentrate is pumped into a centrifugal spray drying tower, the inlet air temperature is set to 120℃ and the outlet air temperature is controlled to 50℃ for spray drying, the bottom powder is collected and sieved through a 70-mesh vibrating screen at 22℃ to obtain the target compound preparation.
[0087] Example 3:
[0088] This embodiment provides a process for a highly absorbable branched-chain amino acid complex formulation that promotes skeletal muscle repair, comprising the following steps:
[0089] Take 1500 parts of buffer microemulsion dispersion C, keep the temperature constant at 25℃, add 50 parts of L-leucine, 25 parts of L-isoleucine and 25 parts of L-valine, turn on the anchor stirrer and stir at 300 rpm for 30 min, then add 8 parts of taurine and 2 parts of grape seed extract in sequence, and continue stirring for 20 min.
[0090] The solution is filtered through a multi-stage precision microporous membrane with a pore size of 10μm to remove trace amounts of insoluble impurities introduced by raw materials such as grape seed extract. The filtered homogenized stock solution is then pumped into an ultrasonic reactor equipped with a refrigerant jacket, maintaining the solution temperature below 30℃. The ultrasonic generator is then activated at a frequency of 40kHz and a pressure of 1.5W / cm². 3 Sonication was performed at power density for 30 minutes.
[0091] After the ultrasound was completed, the liquid was transferred to a constant temperature reactor and the temperature was set to 35°C. 20 parts of chitosan oligosaccharide were slowly added while stirring at 100 rpm. The pH of the reaction system was kept constant and the reaction was continued for 90 min.
[0092] After the reaction is complete, ice water is introduced into the jacket to rapidly cool the system to 15°C within 15 minutes to terminate the reaction. The liquid is then sent to a falling film concentrator and concentrated to a solids concentration of 35% under a vacuum of -0.10 MPa and an evaporation temperature of 45°C.
[0093] The concentrate is pumped into a centrifugal spray drying tower, the inlet air temperature is set to 130℃ and the outlet air temperature is controlled to 60℃ for spray drying, the bottom powder is collected and sieved through an 80-mesh vibrating screen at 25℃ to obtain the target compound preparation.
[0094] Example 4:
[0095] This embodiment provides a process for a highly absorbable branched-chain amino acid complex formulation that promotes skeletal muscle repair, comprising the following steps:
[0096] Take 1000 parts of buffer microemulsion dispersion base liquid B, keep the temperature constant at 20℃, add 40 parts of L-leucine, 20 parts of L-isoleucine and 20 parts of L-valine, turn on the anchor impeller, stir at 200 rpm for 25 min, then add 7 parts of taurine and 1.5 parts of grape seed extract in sequence, and continue stirring for 15 min.
[0097] The solution is filtered through a multi-stage precision microporous membrane with a pore size of 8μm to remove trace amounts of insoluble impurities introduced by raw materials such as grape seed extract. The filtered homogenized stock solution is then pumped into an ultrasonic reactor equipped with a refrigerant jacket to maintain the temperature of the solution below 30℃. The ultrasonic generator is then turned on at a frequency of 30kHz and a speed of 1.0W / cm². 3 Sonication was performed at power density for 20 minutes.
[0098] After the ultrasound was completed, the liquid was transferred to a constant temperature reactor and the temperature was set to 25°C. 12 parts of chitosan oligosaccharide were slowly added while stirring at 80 rpm. The pH of the reaction system was kept constant and the reaction was continued for 60 min.
[0099] After the reaction is complete, ice water is introduced into the jacket to rapidly cool the system to 12°C within 12 minutes to terminate the reaction. The liquid is then sent to a falling film concentrator and concentrated to a solids concentration of 30% under a vacuum of -0.09 MPa and an evaporation temperature of 42°C.
[0100] The concentrate is pumped into a centrifugal spray drying tower, the inlet air temperature is set to 120℃ and the outlet air temperature is controlled to 50℃ for spray drying, the bottom powder is collected and sieved through a 70-mesh vibrating screen at 22℃ to obtain the target compound preparation.
[0101] Comparative Example 1:
[0102] Compared with Example 2, the difference is that a buffer microemulsion dispersion base liquid is not used, and the liquid phase stirring, filtration, ultrasonic treatment, isothermal reaction and concentration and drying processes are omitted. The same weight parts of solid powder raw materials in the formula are directly put into a three-dimensional mixer for conventional dry physical mixing. All other aspects are the same.
[0103] Comparative Example 2:
[0104] Compared with Example 2, the difference is that 1000 parts of buffered microemulsion dispersion base liquid B were replaced with 1000 parts of conventional deionized water. That is, no citrate buffer pair was added to the reaction base liquid and no soy lecithin was added. Everything else was the same.
[0105] Comparative Example 3:
[0106] Compared with Example 2, the difference is that the step of pumping the homogenized stock solution into an ultrasonic reactor with a refrigerant jacket for ultrasonic treatment is omitted. The homogenized stock solution after filtering to remove undissolved flocculent matter is directly transferred to a constant temperature reactor to add chitosan oligosaccharide for subsequent reaction. All other steps are the same.
[0107] Comparative Example 4:
[0108] Compared with Example 2, the difference is that chitosan oligosaccharide is not added to the constant temperature reactor, but is replaced by 15 parts of ordinary food-grade maltodextrin in equal amounts, while the rest are the same.
[0109] Comparative Example 5:
[0110] Compared with Example 2, the difference is that the falling film vacuum concentration step is omitted, and in the centrifugal spray drying stage, the low temperature lock-in parameters throughout are changed, the inlet air temperature is set to 180°C and the outlet air temperature is controlled to 90°C for conventional high temperature hot air drying, while the rest are the same.
[0111] Test Example 1:
[0112] This test example selects the homogenized stock solution before ultrasonication in Example 2 as sample A, the stock solution after ultrasonication in Example 2 as sample B, and the final powder after complete reaction and drying in Example 2 as sample C. L-leucine monomer and the dry-mixed powder prepared in Comparative Example 1 are also selected as references for powder wetting properties. The test process includes:
[0113] Take equal volumes of sample A and sample B respectively, and redissolve sample C powder with the same solid content as sample B in deionized water to prepare the test solution;
[0114] Take an equal amount of the test solution and add ninhydrin reagent. Heat the solution in a boiling water bath for 15 minutes. After cooling rapidly to room temperature in cold water, measure the absorbance of each group at a wavelength of 570 nm using a UV-Vis spectrophotometer.
[0115] Take an appropriate amount of L-leucine monomer powder, the dry-mixed powder of Comparative Example 1 and the finished powder of Example 2, and place them in a powder tablet press and press them into flat discs with a constant pressure of 10 MPa.
[0116] A 2 μL drop of deionized water was added to the surface of the tablet using a contact angle meter, and the static contact angle of the water droplet in contact with the surface was recorded using the pendant drop method to characterize the surface physicochemical properties of different samples.
[0117] Table 1. Results of Free Amino Reactivity and Powder Wetting Contact Angle Tests:
[0118] Test object Absorbance of ninhydrin (570 nm) Static contact angle (°) Sample A 0.312 - Sample B 0.847 - Sample C (Example 2) 0.421 24.6 L-Leucine monomer - 103.4 Comparative Example 1 - 98.7
[0119] From Table 1 and Appendix Figure 1 It can be seen that: "-" in Table 1 indicates that the test objects did not undergo the corresponding specific index test. The absorbance of ninhydrin in sample B was higher than that in sample A, which confirms that the ultrasonic treatment at a specific frequency can destroy the hydrophobic cluster structure formed by branched amino acids in the liquid phase, so that the originally shielded end groups are fully exposed. The absorbance of sample C after reconstitution was significantly lower than that of sample B, indicating that in the isothermal reaction stage after the addition of chitosan oligosaccharide, a large number of exposed free amino groups participated in non-covalent interactions such as hydrogen bonding complexation between molecules, which led to the reactive groups being shielded again.
[0120] Contact angle test data show that the static contact angle of the finished product of Example 2 is lower than that of L-leucine monomer and the dry-mixed powder of Comparative Example 1 without liquid-phase supramolecular modification. The powder surface changes from a strongly hydrophobic state to a highly hydrophilic state. From the perspective of macroscopic physicochemical properties, it is proved that chitosan oligosaccharide constructs a stable hydrophilic coating layer around the hydrophobic core through a weak bond self-assembly process. The data mutually confirm the feasibility of the underlying process mechanism of this invention.
[0121] Test Example 2:
[0122] This test example selects the finished powders from Examples 1 to 4, as well as Comparative Examples 1 and 2, as the test subjects. The test process includes:
[0123] Accurately weigh 5g of each test object powder and put them into a beaker containing 100mL of deionized water at 25℃. Turn on the magnetic stirrer and maintain a constant speed of 100rpm. Record the time required from the time the powder comes into contact with the liquid surface until no obvious floating matter or undissolved clumps are visible to the naked eye. This time is recorded as the mixing, wetting and complete dispersion time.
[0124] All the test liquid that has been stirred and dispersed was transferred to a 100mL standard graduated measuring cylinder with a stopper. The cylinder was kept still for 2 hours at room temperature. After the standing time was completed, the volume of the precipitate at the bottom of the measuring cylinder was read. The suspension sedimentation rate of the aqueous solution after standing for 2 hours was calculated by the percentage of the precipitate volume to the total volume of the liquid.
[0125] Table 2. Results of the test on the stability of the powder formulation during reconstitution and dispersion:
[0126] Test object Time for rehydration, wetting, and complete dispersion (s) Suspension sedimentation rate (%) of aqueous solution after standing for 2 hours Example 1 18.4 2.1 Example 2 15.2 1.8 Example 3 16.7 1.9 Example 4 15.8 2.0 Comparative Example 1 314.5 87.3 Comparative Example 2 142.1 45.6
[0127] From Table 2 and Appendix Figure 2It can be seen that the test samples of Examples 1 to 4 had shorter mixing and dispersion times in room temperature water and lower sedimentation rates after standing. Comparative Example 1 did not undergo liquid-phase supramolecular modification treatment, and the hydrophobic side chains of the internal branched amino acids were directly exposed, resulting in severe floating and clumping of the powder after contact with the water surface. The dissolution time was increased and severe solid-liquid phase separation and precipitation occurred after standing. Comparative Example 2 removed the citric acid buffer and soybean lecithin during the preparation process, making it difficult for the material to form a uniform microemulsion dispersion system in the liquid phase substrate, affecting the integrity of the subsequent coating structure. The mixing time and sedimentation rate were higher than those of the Example group. This indicates that the microemulsion dispersion base liquid and chitosan oligosaccharide coating process of the present invention effectively masked the hydrophobic groups, changed the lipid-water distribution state of the formulation powder, and improved the macroscopic physicochemical solubility properties and aqueous suspension stability of the final product.
[0128] Test Example 3:
[0129] This test example selects the finished powders from Examples 1 to 4, as well as Comparative Examples 3 and 4, as the test subjects. The test process includes:
[0130] Accurately weigh 0.5g of each test object powder and disperse it in 50mL of simulated intestinal fluid phosphate buffer with a pH of 6.8 to prepare the sample test solution;
[0131] Weigh an appropriate amount of purified porcine gastric mucin and dissolve it in the same buffer solution to prepare a mucin standard solution with a concentration of 2.0 mg / mL;
[0132] Mix the test solutions of each sample with the mucin standard solution in equal volumes, place them in a constant temperature water bath shaker set at 37℃, and incubate at 120 rpm for 2 hours.
[0133] After the reaction was completed, the mixture was transferred to a centrifuge tube and centrifuged at 8000 rpm for 15 min to precipitate the conjugate.
[0134] The supernatant was collected, and the absorbance was measured at a specific wavelength using a UV-Vis spectrophotometer. The concentration of the remaining free mucin in the supernatant was calculated by converting it with a pre-plotted mucin standard curve, and the in vitro mucin adsorption and binding rate was calculated based on the initial mucin concentration.
[0135] Table 3. Results of in vitro mucin adsorption and binding rate test:
[0136] Test object In vitro mucin adsorption and binding rate (%) Example 1 68.4 Example 2 71.9 Example 3 74.2 Example 4 70.6 Comparative Example 3 31.5 Comparative Example 4 14.8
[0137] From Table 3 and Appendix Figure 3It can be seen that the test samples of Examples 1 to 4 recorded relatively high in vitro mucin adsorption and binding rates. In Comparative Example 3, the ultrasonic cavitation depolymerization step was omitted in the process flow, and the cluster state of branched amino acids in the liquid system was not fully dissociated, which affected the physical integrity of chitosan oligosaccharide on the hydrophobic core during supramolecular recombination, resulting in a lower mucin adsorption amount in the final formulation. In Comparative Example 4, the chitosan oligosaccharide in the formulation was replaced with an equal amount of maltodextrin. The surface of the finished powder lacked a large number of hydroxyl and amino polar groups with specific spatial configurations, which inhibited the hydrogen bonding and dipole interaction between the particles and the mucin molecules in the mucus layer in the aqueous phase. The measured adsorption and binding rate decreased significantly. The test values indicate that the surface of the composite particles prepared by the conformation extension and chitosan oligosaccharide weak bond assembly process has the physicochemical conditions to interact with digestive tract mucin.
[0138] Test Example 4:
[0139] This test example selects the finished powder from Examples 1 to 4 and Comparative Example 1 as the test objects. The test process includes:
[0140] Weigh out equal amounts of each group of powder samples containing the same branched-chain amino acid equivalents and place them in the dissolution cup of the dissolution apparatus; first add 900 mL of simulated gastric fluid preheated to 37°C and pH 1.2, set the paddle speed to 100 rpm and start timing;
[0141] At 0.5h and 1h, 5mL of release medium was aspirated as a sampling solution, and an isothermal and equal-volume blank simulated gastric fluid was immediately added to the dissolution vessel. After 1h, the pH of the remaining medium was rapidly adjusted to 6.8 using sodium phosphate to convert it into a simulated artificial intestinal fluid environment for further in vitro dissolution testing. At 2h and 4h, 5mL of release medium was aspirated again.
[0142] The samples collected at each time point were filtered through a microporous membrane, and the concentration of branched-chain amino acids in the filtrate was determined using a high-performance liquid chromatograph. The cumulative dissolution percentage was calculated based on the concentration values at each time point.
[0143] Table 4. Cumulative dissolution test results of simulated gastrointestinal fluid at different time points:
[0144] Test object Cumulative dissolution rate (%) over 0.5 hours Cumulative dissolution rate (%) over 1 hour Cumulative dissolution rate over 2 hours (%) Cumulative dissolution rate over 4 hours (%) Example 1 8.4 15.2 46.7 85.3 Example 2 7.1 13.5 41.2 82.1 Example 3 9.2 16.8 48.9 88.6 Example 4 7.8 14.3 43.5 83.9 Comparative Example 1 48.5 89.2 92.4 94.1
[0145] From Table 4 and Appendix Figure 4It can be seen that: Comparative Example 1 uses a conventional dry physical mixing process. The internal amino acid crystals lack an outer physical protective structure. In the initial stage of contact with simulated gastric juice, a large amount of drug dissolution occurs, exhibiting burst release characteristics. The release characteristics cause the substance to dissociate prematurely at the front of the digestive tract and be emptied with the fluid. The cumulative dissolution of the test samples in Examples 1 to 4 in the simulated gastric juice environment with a pH of 1.2 remained at a low level in the first hour. After switching to the simulated intestinal juice environment with a pH of 6.8, the dissolution showed a smooth increase in the sustained release curve. The test data shows that the external physical coating layer formed by chitosan oligosaccharide through non-covalent interactions such as hydrogen bonding and electrostatic attraction maintains a relatively stable spatial structure in a strongly acidic environment, reducing the rate of water molecule penetration into the core. As the liquid environment changes to the characteristics of intestinal juice, the macromolecular network gradually absorbs water, swells and relaxes, exhibiting a stable release characteristic that conforms to the long-term absorption characteristics of organisms.
[0146] Test Example 5:
[0147] This test example selects the finished powders from Examples 1 to 4 and Comparative Example 5 as the test subjects. The test process includes:
[0148] Each test object powder sample was accurately weighed, and the proanthocyanidin component was extracted using ethanol aqueous solution with ultrasonic assistance. The absorbance of the extract was measured in a UV-Vis spectrophotometer using the vanillin-hydrochloric acid colorimetric method, and the proanthocyanidin retention rate was calculated based on the initial formula input.
[0149] Each group of powder samples was redissolved in deionized water to prepare a test solution with a specific mass concentration. An appropriate amount of the solution was taken and the absorbance value was directly measured at a wavelength of 420 nm using a spectrophotometer. This was used as the browning index to characterize the degree of Maillard reaction of amino acids upon heating.
[0150] Weigh each group of powders again to prepare sample solutions of the same concentration, mix them with a certain concentration of DPPH anhydrous ethanol solution in volume ratio, and let them stand for 30 minutes at room temperature in the dark.
[0151] After the reaction was completed, the absorbance of the reaction system was measured at a wavelength of 517 nm using a spectrophotometer, and the percentage of DPPH free radical scavenging rate of each sample was calculated based on the measured values.
[0152] Table 5. Results of Low-Temperature Inactivation and Antioxidant Potency Retention Tests:
[0153] Test object Proanthocyanidin retention rate (%) Browning index (420nm) DPPH free radical scavenging rate (%) Example 1 89.4 0.08 81.2 Example 2 91.7 0.06 84.5 Example 3 88.2 0.09 78.9 Example 4 90.1 0.07 82.3 Comparative Example 5 23.6 0.74 28.4
[0154] From Table 5 and Appendix Figure 5It can be seen that: Comparative Example 5 adopted a conventional high-temperature hot air spray drying process. The high inlet and outlet air temperatures caused the amino acid end groups in the system to undergo Maillard browning reaction during the dehydration heating process, and the browning index value showed a significant increase. At the same time, the high-temperature physical stress caused a large amount of degradation of the heat-sensitive grape seed proanthocyanidins in the formulation. The measured proanthocyanidin retention rate and DPPH free radical scavenging rate were both at a low level. The test objects of Examples 1 to 4 adopted negative pressure concentration and low-temperature dehydration processes during the preparation process. The actual heating temperature of the materials was always controlled within a low range. The test data showed that the combination of process parameters inhibited the browning phenomenon between free amino and carboxyl molecules, and the browning index of the powder was maintained at a low level. While retaining the physical structure of branched amino acids, the loss of heat-sensitive antioxidants was reduced. After reconstitution, the relevant powders showed a high DPPH free radical scavenging value. The test results verified the actual role of the low-temperature processing parameters set in this invention in maintaining the antioxidant physicochemical efficacy of the formulation.
[0155] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.
Claims
1. A highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair, characterized in that, The composite formulation forms a physical encapsulation structure through non-covalent interactions between chitosan oligosaccharides and branched-chain amino acids, which promotes skeletal muscle repair and enhances the adsorption and binding rate of the intestinal mucosa; the composite formulation comprises the following components in parts by weight: Buffered microemulsion dispersion base: 735 to 1500 parts; L-Leucine: 30 to 50 parts; L-Isoleucine: 15 to 25 parts; L-valine: 15 to 25 parts; Taurine: 3 to 8 parts; Grape seed extract: 0.5 to 2 parts; Chitosan oligosaccharide: 10 to 20 parts.
2. The highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair according to claim 1, characterized in that, The buffered microemulsion dispersion consists of deionized water, a buffer system composed of citric acid and sodium citrate dihydrate, and soybean lecithin, and the pH value of the buffered microemulsion dispersion is constantly controlled within the range of 3.5 to 4.
5.
3. The highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair according to claim 1, characterized in that, The degree of polymerization of the chitosan oligosaccharide is between 2 and 10, the number average molecular weight is between 500 Da and 2000 Da, and the degree of deacetylation is ≥90%; the mass fraction of proanthocyanidins in the grape seed extract is ≥95%.
4. A process for a highly absorbable branched-chain amino acid complex formulation for promoting skeletal muscle repair according to any one of claims 1-3, characterized in that, Includes the following steps: L-Leucine, L-Isoleucine and L-Valine were added to a buffer microemulsion dispersion solution controlled at a constant temperature. After stirring and mixing, taurine and grape seed extract were added in sequence, and stirring was continued to obtain a homogeneous stock solution. The homogenized stock solution was pumped into an ultrasonic reactor with a refrigerant jacket for ultrasonic treatment, which opened the hydrophobic cluster structure of the branched amino acid molecules and exposed the active sites of the side chains. After the ultrasound is completed, the liquid is transferred to a constant temperature reactor and chitosan oligosaccharide is slowly added. The reaction is continued while maintaining a constant pH value in the reaction system to promote the formation of a weak bond cross-linking coating structure between chitosan oligosaccharide and branched-chain amino acid molecules. After the reaction is completed, the temperature is rapidly reduced to terminate the reaction. After the reaction is terminated, the liquid is sent to a falling film concentrator for vacuum negative pressure concentration. Then, the concentrate is pumped into a centrifugal spray drying tower for low-temperature spray drying. The bottom powder is collected and sieved to obtain the target compound formulation.
5. The process for the highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair according to claim 4, characterized in that, The step of pumping the homogenized stock solution into an ultrasonic reactor with a refrigerant jacket for ultrasonic treatment to open the hydrophobic cluster structure of branched amino acid molecules and expose the active sites of the side chains includes: Before ultrasonic treatment, the homogenized stock solution is filtered through a multi-stage precision microporous membrane with a pore size of 5 to 10 μm to remove insoluble impurities introduced by the raw materials.
6. The process for the highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair according to claim 4, characterized in that, The step of pumping the homogenized stock solution into an ultrasonic reactor with a refrigerant jacket for ultrasonic treatment to open the hydrophobic cluster structure of branched amino acid molecules and expose the active sites of the side chains includes: Maintain the temperature of the molten material below 30°C, set the ultrasonic frequency to 20 to 40 kHz, and the ultrasonic power density to 0.5 to 1.5 W / cm³. 3 The ultrasonic treatment time is 15 to 30 minutes.
7. The process for the highly absorbable branched-chain amino acid complex formulation for promoting skeletal muscle repair according to claim 4, characterized in that, After the ultrasound is completed, the liquid is transferred to a constant-temperature reactor and chitosan oligosaccharide is slowly added. The reaction is continued while maintaining a constant pH value in the reaction system, which promotes the formation of a weakly cross-linked coating structure between the chitosan oligosaccharide and branched-chain amino acid molecules. The step of rapidly cooling to terminate the reaction after the reaction is completed includes: The temperature for the isothermal reaction after adding chitosan oligosaccharide was set at 20 to 35°C, the stirring speed at 50 to 100 rpm, and the reaction time at 45 to 90 min. Ice water was introduced into the jacket of the reactor to rapidly cool the system to 10 to 15°C within 10 to 15 min to terminate the reaction.
8. The process for the highly absorbable branched-chain amino acid complex preparation for promoting skeletal muscle repair according to claim 4, characterized in that, The step of sending the terminated reaction solution into a falling film concentrator for vacuum negative pressure concentration includes: Vacuum negative pressure concentration was carried out at a vacuum degree of -0.08MPa to -0.10MPa and an evaporation temperature controlled between 40 and 45℃, and the solid concentration of the concentrated liquid was controlled to be between 25% and 35%.
9. The process for the highly absorbable branched-chain amino acid complex formulation for promoting skeletal muscle repair according to claim 4, characterized in that, The subsequent steps of pumping the concentrate into a centrifugal spray drying tower for low-temperature spray drying, collecting the bottom powder and sieving it to obtain the target compound formulation include: Low-temperature spray drying is performed by setting the inlet air temperature to 110 to 130°C and the outlet air temperature to 45 to 60°C; the product is then sieved using a 60 to 80 mesh vibrating screen at an environment of 20 to 25°C.
10. The process for the highly absorbable branched-chain amino acid complex formulation for promoting skeletal muscle repair according to claim 4, characterized in that, The step of adding L-leucine, L-isoleucine, and L-valine to a buffer microemulsion dispersion under constant temperature conditions, stirring and mixing, then sequentially adding taurine and grape seed extract, and continuing stirring to obtain a homogeneous stock solution includes: The buffered microemulsion dispersion was kept at a constant temperature of 15 to 25°C. L-leucine, L-isoleucine and L-valine were added and stirred at 150 to 300 rpm for 20 to 30 minutes. Taurine and grape seed extract were then added sequentially and stirred for another 10 to 20 minutes.
